UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

The Lancet (British edition), 2019-07, Vol.394 (10192), p.39-50

2019

Volltextzugriff (PDF)

Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

The American heart journal, 2021-12, Vol.242, p.160-160

2021

Volltextzugriff (PDF)

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

Diabetes care, 2010-03, Vol.33 (3), p.605-607

2010

Volltextzugriff (PDF)

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2012-07, Vol.17 (2), p.S1-S95

2012

Volltextzugriff (PDF)

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

The New England journal of medicine, 2020-12, Vol.383 (23), p.2219-2229

2020

Volltextzugriff (PDF)

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

The New England journal of medicine, 2021-12, Vol.385 (24), p.2252-2263

2021

Volltextzugriff (PDF)

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

The New England journal of medicine, 2017-08, Vol.377 (8), p.723-732

2017

Volltextzugriff (PDF)

Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management

Diabetologia, 2024-08

2024

Volltextzugriff (PDF)

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2012-04, Vol.17 (1), p.61-62

Amod, Aslam

2012

Volltextzugriff (PDF)

930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis

Annals of internal medicine, 2023-12, Vol.176 (12), p.1606-1616

2023

Volltextzugriff (PDF)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Diabetes care, 2022-04, Vol.45 (4), p.888-e897

2022

Volltextzugriff (PDF)

406-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Abstract #1305594: Real-Life Effectiveness and Care Patterns of Diabetes Management in Eastern Europe, Middle East, and Africa (RECAP-DM EEMEA STUDY)

Endocrine practice, 2022-12, Vol.28 (12), p.S14-S14

2022

Volltextzugriff (PDF)

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes : editorial

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2012-01, Vol.17 (1), p.61-62

Amod, Aslam

2012

Volltextzugriff (PDF)

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program

Indian journal of endocrinology and metabolism, 2022-03, Vol.26 (Suppl 1), p.S47-S48

2022

Volltextzugriff (PDF)

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897

Diabetes care, 2023-09, Vol.46 (9), p.1721-1721

2023

Volltextzugriff (PDF)

60 - Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

Canadian journal of diabetes, 2020-10, Vol.44 (7), p.S26-S26

2020

Volltextzugriff (PDF)

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Position statement on the use of HbA1C assays for the diagnosis of diabetes mellitus: The Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA)

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2010-07, Vol.15 (2), p.71-73

Amod, Aslam

2010

Volltextzugriff (PDF)

Chronic Kidney Disease (CKD) and Risk of Mortality, Cardiovascular (CV) Events, and Severe Hypoglycemia in Type 2 Diabetes (T2D)-DEVOTE Results

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin

Endocrine practice, 2014-11, Vol.20 (11), p.1143-1150

2014

Volltextzugriff (PDF)

45th SEMDSA Congress 2010

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2010-04, Vol.15 (1), p.4-4

Amod, Aslam

2010

Volltextzugriff (PDF)

45th SEMDSA Congress 2010 : editorial

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2010-01, Vol.15 (1), p.4

Amod, Aslam

2010

Volltextzugriff (PDF)

Position statement on the use of HbA1C assays for the diagnosis of diabetes mellitus - The Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) : SEMDSA position statement

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2010-01, Vol.15 (2), p.71-73

Amod, Aslam

2010

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Humans
(10)
Endocrinology & Metabolism
(9)
Diabetes
(7)
Diabetes Mellitus, Type 2 - Complications
(7)
Diabetes Mellitus, Type 2 - Drug Therapy
(7)
Female
(7)
Male
(7)
Diabetes Mellitus
(6)
Double-Blind Method
(6)
General & Internal Medicine
(6)
Medicine, General & Internal
(6)
Middle Aged
(6)
Patients
(6)
Aged
(5)
Clinical Trials
(5)
Epidermal Growth Factor Receptors
(5)
Glomerular Filtration Rate
(5)
Hyperkalemia
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes

930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

406-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment

Abstract #1305594: Real-Life Effectiveness and Care Patterns of Diabetes Management in Eastern Europe, Middle East, and Africa (RECAP-DM EEMEA STUDY)

The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes : editorial

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897

60 - Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

Position statement on the use of HbA1C assays for the diagnosis of diabetes mellitus: The Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA)

Chronic Kidney Disease (CKD) and Risk of Mortality, Cardiovascular (CV) Events, and Severe Hypoglycemia in Type 2 Diabetes (T2D)-DEVOTE Results

A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin

45th SEMDSA Congress 2010

45th SEMDSA Congress 2010 : editorial

Position statement on the use of HbA1C assays for the diagnosis of diabetes mellitus - The Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) : SEMDSA position statement

Aktive Filter

Suchergebnisse filtern